Published in Pulm Pharmacol Ther on July 12, 2005
Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res (2010) 1.79
Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol (2011) 1.35
Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) (2010) 1.13
Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 1.11
Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res (2010) 1.02
Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study. COPD (2009) 0.99
Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm Med (2012) 0.94
Serum cytokine profiling and enrichment analysis reveal the involvement of immunological and inflammatory pathways in stable patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.92
Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One (2013) 0.89
Defining disease modification in chronic obstructive pulmonary disease. COPD (2009) 0.85
Reduced exercise tolerance and pulmonary capillary recruitment with remote secondhand smoke exposure. PLoS One (2012) 0.85
Trachea epithelium as a "canary" for cigarette smoking-induced biologic phenotype of the small airway epithelium. Clin Transl Sci (2009) 0.84
Oral non-typable Haemophilus influenzae enhances physiological mechanism of airways protection. Clin Exp Immunol (2010) 0.83
Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med (2016) 0.81
Biomarkers in COPD: time for a deep breath. Thorax (2007) 0.80
Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics (2010) 0.80
Data mining of plasma peptide chromatograms for biomarkers of air contaminant exposures. Proteome Sci (2008) 0.79
Reactive oxygen species in peripheral blood and sputum neutrophils during bacterial and nonbacterial acute exacerbation of chronic obstructive pulmonary disease. Inflammation (2013) 0.79
Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. Respir Res (2009) 0.77
Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD). Pharm Res (2014) 0.77
Chinese herbal medicine (weijing decoction) combined with pharmacotherapy for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Evid Based Complement Alternat Med (2014) 0.76
Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway. Respir Res (2015) 0.76
The holistic perspective of chronic obstructive pulmonary disease: doubt some more. Ther Adv Chronic Dis (2010) 0.75
Autoantibodies against CD80 in patients with COPD. Clin Transl Immunology (2016) 0.75
Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques. Pharm Res (2015) 0.75
Serum Vitamin A and Inflammatory Markers in Individuals with and without Chronic Obstructive Pulmonary Disease. Mediators Inflamm (2015) 0.75
Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease: Results From the INSPIRE-II Trial. Psychosom Med (2016) 0.75
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomark Insights (2017) 0.75
The association of tidal EFL with exercise performance, exacerbations, and death in COPD. Int J Chron Obstruct Pulmon Dis (2017) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med (2011) 7.92
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet (2004) 6.17
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
From COPD to chronic systemic inflammatory syndrome? Lancet (2007) 4.13
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA (2010) 4.08
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Management of non-small-cell lung cancer: recent developments. Lancet (2013) 3.51
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med (2004) 3.26
Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. JAMA (2013) 3.13
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol (2010) 3.12
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. Am J Respir Crit Care Med (2011) 2.93
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Point: should we abandon FEV₁/FVC <0.70 to detect airway obstruction? No. Chest (2010) 2.89
"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med (2004) 2.77
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Gender and COPD in patients attending a pulmonary clinic. Chest (2005) 2.59
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42
Internet-based self-management plus education compared with usual care in asthma: a randomized trial. Ann Intern Med (2009) 2.37
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
Treating COPD--the TORCH trial, P values, and the Dodo. N Engl J Med (2007) 2.26
Systemic manifestations of COPD. Chest (2011) 2.25
Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med (2013) 2.24
Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J (2012) 2.18
The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol (2003) 2.15
The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med (2011) 2.15
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.13
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood (2007) 2.10
Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med (2010) 2.09
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 2.02
The European Respiratory Society plans its future: the 2013-2018 strategic plan. Eur Respir J (2014) 2.02
Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care (2006) 2.00
The Asthma-COPD Overlap Syndrome. N Engl J Med (2015) 1.99
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. J Clin Pharmacol (2014) 1.99
C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest (2008) 1.98
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J (2005) 1.95
Responsiveness of the Neck Disability Index in patients with mechanical neck disorders. Spine J (2009) 1.94
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
Bronchodilator reversibility in COPD. Chest (2011) 1.89
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood (2014) 1.87
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood (2013) 1.84
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol (2008) 1.83
Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80
An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer (2008) 1.80
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood (2009) 1.80
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One (2011) 1.78
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Pharmacology and therapeutics of bronchodilators. Pharmacol Rev (2012) 1.72
Phosphodiesterase inhibitors. Br J Pharmacol (2006) 1.72
The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol (2010) 1.71
Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med (2009) 1.70
Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2009) 1.70
EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer (2008) 1.69
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol (2008) 1.68
Bronchial inflammation and airway responses to deep inspiration in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.68
Novel drug development opportunities for heparin. Nat Rev Drug Discov (2002) 1.68
Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med (2005) 1.67
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol (2007) 1.64
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.63
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood (2011) 1.63
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax (2007) 1.62
Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med (2011) 1.61
EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol (2009) 1.60
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59
Lung volume reduction therapies for advanced emphysema: an update. Chest (2010) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Care Med (2003) 1.56
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Lung volume reduction surgery vs medical treatment: for patients with advanced emphysema. Chest (2005) 1.54
Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood (2004) 1.53
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One (2008) 1.52
Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest (2013) 1.51
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet (2011) 1.51
An evidence-based estimate on the size of the potential patient pool for lung volume reduction surgery. Ann Thorac Surg (2012) 1.50